ChemoCentryx Inc (NASDAQ:CCXI) major shareholder (International) Ltd Vifor sold 88,012 shares of the business’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $52.58, for a total transaction of $4,627,670.96. The sale was disclosed in a document filed with the SEC, which is available through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

(International) Ltd Vifor also recently made the following trade(s):

  • On Monday, July 27th, (International) Ltd Vifor sold 34,236 shares of ChemoCentryx stock. The stock was sold at an average price of $53.32, for a total transaction of $1,825,463.52.
  • On Wednesday, July 22nd, (International) Ltd Vifor sold 72,469 shares of ChemoCentryx stock. The stock was sold at an average price of $55.58, for a total transaction of $4,027,827.02.
  • On Friday, July 24th, (International) Ltd Vifor sold 133,074 shares of ChemoCentryx stock. The stock was sold at an average price of $54.62, for a total transaction of $7,268,501.88.
  • On Monday, July 20th, (International) Ltd Vifor sold 54,598 shares of ChemoCentryx stock. The stock was sold at an average price of $56.03, for a total transaction of $3,059,125.94.
  • On Friday, July 17th, (International) Ltd Vifor sold 47,890 shares of ChemoCentryx stock. The stock was sold at an average price of $55.86, for a total transaction of $2,675,135.40.
  • On Wednesday, July 15th, (International) Ltd Vifor sold 86,298 shares of ChemoCentryx stock. The stock was sold at an average price of $59.22, for a total transaction of $5,110,567.56.
  • On Monday, July 13th, (International) Ltd Vifor sold 100,000 shares of ChemoCentryx stock. The stock was sold at an average price of $58.15, for a total transaction of $5,815,000.00.
  • On Friday, July 10th, (International) Ltd Vifor sold 45,844 shares of ChemoCentryx stock. The stock was sold at an average price of $59.92, for a total transaction of $2,746,972.48.
  • On Wednesday, July 8th, (International) Ltd Vifor sold 100,000 shares of ChemoCentryx stock. The stock was sold at an average price of $59.95, for a total transaction of $5,995,000.00.
  • On Monday, July 6th, (International) Ltd Vifor sold 86,690 shares of ChemoCentryx stock. The stock was sold at an average price of $58.44, for a total transaction of $5,066,163.60.

NASDAQ:CCXI opened at $52.71 on Friday. ChemoCentryx Inc has a 12-month low of $6.16 and a 12-month high of $65.43. The company has a quick ratio of 3.22, a current ratio of 3.22 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $3.26 billion, a PE ratio of -48.36 and a beta of 2.04. The firm has a 50-day moving average price of $57.54 and a 200 day moving average price of $50.31.

ChemoCentryx (NASDAQ:CCXI) last posted its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.05). ChemoCentryx had a negative return on equity of 100.55% and a negative net margin of 192.93%. The business had revenue of $6.01 million during the quarter, compared to analyst estimates of $8.90 million. On average, research analysts expect that ChemoCentryx Inc will post -1.39 EPS for the current year.

A number of research firms have weighed in on CCXI. Canaccord Genuity reissued a “buy” rating on shares of ChemoCentryx in a research report on Wednesday, June 3rd. ValuEngine lowered shares of ChemoCentryx from a “buy” rating to a “hold” rating in a research report on Thursday, July 2nd. BTIG Research began coverage on shares of ChemoCentryx in a research report on Tuesday, June 16th. They set a “buy” rating and a $70.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $69.00 target price on shares of ChemoCentryx in a research report on Monday, May 18th. Finally, JPMorgan Chase & Co. cut their price objective on shares of ChemoCentryx from $64.00 to $61.00 and set an “overweight” rating for the company in a research report on Wednesday. Two research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $68.70.

A number of large investors have recently bought and sold shares of the stock. Mackay Shields LLC raised its position in ChemoCentryx by 22.6% in the second quarter. Mackay Shields LLC now owns 35,800 shares of the biopharmaceutical company’s stock worth $2,060,000 after purchasing an additional 6,600 shares in the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in ChemoCentryx in the second quarter worth about $475,000. Raymond James & Associates raised its position in ChemoCentryx by 11.6% in the second quarter. Raymond James & Associates now owns 63,637 shares of the biopharmaceutical company’s stock worth $3,662,000 after purchasing an additional 6,634 shares in the last quarter. Emerald Advisers LLC raised its position in ChemoCentryx by 7.2% in the second quarter. Emerald Advisers LLC now owns 401,839 shares of the biopharmaceutical company’s stock worth $23,122,000 after purchasing an additional 27,105 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in ChemoCentryx by 70.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,398 shares of the biopharmaceutical company’s stock worth $253,000 after buying an additional 1,812 shares during the last quarter. 70.37% of the stock is owned by hedge funds and other institutional investors.

ChemoCentryx Company Profile

ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy.

Recommended Story: What is meant by holder of record?

Insider Buying and Selling by Quarter for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.